Dapivirine vs Etravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Dapivirine · Dapivirine Vaginal Ring

Marketed by Population Council and partners

Phase 3 in HIVsmall molecule
Reliable signal

NCT01617096 · Phase 3 · completed

This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.

Reported efficacy

Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)

Result source: NCT01617096

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDapivirineEtravirine
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0625050456% vs 39%a+17 vs placebowk 24NCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06250504—Not posted · NCT00255099
CD4 count, change (week 48)—Trial running · NCT06250504—Not posted · NCT00255099

HIV-1 RNA below 50 copies/mL (week 48)

Dapivirine
—Trial running · NCT06250504
Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046

HIV-1 RNA 50 copies/mL or more (week 48)

Dapivirine
—Trial running · NCT06250504
Etravirine
—Not posted · NCT00255099

CD4 count, change (week 48)

Dapivirine
—Trial running · NCT06250504
Etravirine
—Not posted · NCT00255099
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapivirine: 4 of 4 rows · Etravirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapivirineEtravirine
Dropout rate
11.3%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
9.9%25 mg
NCT02862171 · Phase 3
3.6%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
5.5%
NCT02028338 · Phase 2 · registry result, not featured evidence
2.8%
NCT02010593 · Phase 2 · registry result, not featured evidence
20.9%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
23.3%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
10.5%
NCT03239483 · Phase 1 · registry result, not featured evidence
31%
NCT01539226 · Phase na · registry result, not featured evidence
n/a: no completion milestonea
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
—25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
—25 mg
NCT02862171 · Phase 3
—25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
—
NCT02028338 · Phase 2 · registry result, not featured evidence
—
NCT02010593 · Phase 2 · registry result, not featured evidence
4.7%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
—
NCT03239483 · Phase 1 · registry result, not featured evidence
0%
NCT01539226 · Phase na · registry result, not featured evidence
6.7%a
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Serious AEs
8.8%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
2.1%25 mg
NCT02862171 · Phase 3
1.4%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
0%
NCT03593655 · Phase 2 · registry result, not featured evidence
2.7%
NCT02028338 · Phase 2 · registry result, not featured evidence
1.4%
NCT02010593 · Phase 2 · registry result, not featured evidence
2.3%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%
NCT03239483 · Phase 1 · registry result, not featured evidence
3.1%
NCT01539226 · Phase na · registry result, not featured evidence
10%a
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
25 mg DVR inserted once every 4 weeksa
metrorrhagia 55.1% (placebo 55.6%)
genitourinary chlamydia infection 20.5% (placebo 20.8%)
menorrhagia 19.7% (placebo 18.4%)
NCT01617096 · Phase 3 · monotherapy
show 9 more results
25 mg
infections 49.1%
reproductive system 20.9%
headache 3.5%
NCT02862171 · Phase 3
25 mg vaginal matrix ring
genitourinary chlamydia infection 8.4%
vaginal discharge 8%
vulvovaginitis trichomonal 5.9%
NCT02858037 · Phase 3 · registry result, not featured evidence
any event in soc 58.5%
any event in soc 32.4%
creatinine renal clearance decreased 30.3%
NCT03593655 · Phase 2 · registry result, not featured evidence
metrorrhagia 20.5% (placebo 26.1%)
vaginal discharge 15.1% (placebo 34.8%)
bacterial vaginosis 12.3% (placebo 8.7%)
NCT02028338 · Phase 2 · registry result, not featured evidence
vaginal discharge 11.1% (placebo 12.5%)
upper respiratory tract infection 8.3% (placebo 12.5%)
vaginal odour 6.9% (placebo 0%)
NCT02010593 · Phase 2 · registry result, not featured evidence
vaginitis bacterial 16.3% (placebo 11.9%)
vaginal candidiasis 9.3% (placebo 0%)
abdominal pain lower 4.7% (placebo 0%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
vaginitis bacterial 34.9% (placebo 11.9%)
vulvovaginal pruritus 9.3% (placebo 4.8%)
headache 7% (placebo 7.1%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
diarrhoea 11.1% (placebo 22.2%)
insomnia 11.1% (placebo 0%)
anal pruritus 5.6% (placebo 0%)
NCT03239483 · Phase 1 · registry result, not featured evidence
gynaecological chlamydia infection 32.7% (placebo 32.7%)
metrorrhagia 27% (placebo 29.6%)
genital infection female 23% (placebo 19.3%)
NCT01539226 · Phase na · registry result, not featured evidence
a
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapivirine

HIV-1 Incidence Rate Per 100 PY 2.7 count @ 56.5wk25 mg vaginal matrix ring
event rate · count
No placebo or comparator arm
NCT02858037 · Phase 3 · registry result, not featured evidence
HIV-2 Seroconversion 0% (n=1302) vs 0% (n=650) placebo @ 104wk
event count · % of participants
NCT01539226 · Phase na · registry result, not featured evidence · converted to % from 0 Participants as posted

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4+ 156 cells/uL @ 24wk400 mg once daily
absolute change · cells/uL
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 7 more results
163 cells/uL @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
224 cells/uL @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
156 cells/uL @ 48wk
NCT00665847 · Phase 2 · registry result, not featured evidence
21.5 cells/uL @ 48wk
NCT00128830 · Phase 2 · registry result, not featured evidence
18.5 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
120 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
149.5 cells/uL @ 192wk
NCT00128830 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA -1.8 copies/mL @ 4wk400/100 mg
absolute change · copies/mL
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-2 copies/mL @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.9 copies/mL @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.7 copies/mL @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -1.53 log @ 48wk
absolute change · log
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk
event count · % of participants
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more result
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Etravirine's landscape